Separately, BWS Financial assumed coverage on shares of Assertio in a research note on Wednesday, May 18th. They set a “buy” rating for the company.
NASDAQ ASRT opened at $2.76 on Wednesday. The company has a quick ratio of 0.83, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a fifty day moving average of $2.76 and a two-hundred day moving average of $2.47. The firm has a market capitalization of $125.40 million, a price-to-earnings ratio of 46.00, a PEG ratio of 0.77 and a beta of 1.57. Assertio has a 52 week low of $0.85 and a 52 week high of $3.52.
In related news, Director James L. Tyree sold 44,643 shares of Assertio stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $2.36, for a total value of $105,357.48. Following the completion of the sale, the director now directly owns 210,451 shares in the company, valued at $496,664.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel A. Peisert sold 26,391 shares of Assertio stock in a transaction dated Monday, April 11th. The shares were sold at an average price of $3.50, for a total value of $92,368.50. Following the completion of the sale, the chief executive officer now owns 158,402 shares of the company’s stock, valued at $554,407. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 105,552 shares of company stock valued at $318,539. Corporate insiders own 2.50% of the company’s stock.
A number of institutional investors have recently made changes to their positions in ASRT. Jane Street Group LLC grew its stake in shares of Assertio by 102.6% during the first quarter. Jane Street Group LLC now owns 41,371 shares of the company’s stock worth $119,000 after acquiring an additional 20,952 shares during the last quarter. Divisadero Street Capital Management LP purchased a new stake in shares of Assertio during the first quarter worth about $169,000. Atria Wealth Solutions Inc. purchased a new stake in Assertio in the first quarter valued at approximately $43,000. Invesco Ltd. boosted its position in Assertio by 64.6% in the first quarter. Invesco Ltd. now owns 182,970 shares of the company’s stock valued at $525,000 after buying an additional 71,829 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Assertio by 621.1% in the first quarter. Renaissance Technologies LLC now owns 92,300 shares of the company’s stock valued at $265,000 after buying an additional 79,500 shares during the last quarter. Institutional investors and hedge funds own 15.64% of the company’s stock.
About Assertio (Get Rating)
Assertio Holdings, Inc, a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
- Get a free copy of the StockNews.com research report on Assertio (ASRT)
- Could This Cheap Energy Stock With A 7% Dividend Yield Be Right for Your Portfolio?
- The Zedge Hypergrowth Story Is Played Out
- Is This A Buyable Bottom For Braze, Inc Shares?
- What To Make Of Tesla Right Now
- NortonLifeLock: Developments in Avast Merger and Improved Fundamentals
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.